The AlphaLISA® Human Plasminogen Activator Inhibitor-1 (PAI-1) Detection Kit is designed for detection and quantitation of human PAI-1 in serum, buffered solution or cell culture medium in a homogeneous (no-wash steps, no separation steps) assay. The analyte in this kit consists of the active glycosylated human PAI-1.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Product Number||List Price||Your Price||Quantity|
You successfully added item(s) to your cart
Plasminogen activator inhibitor-1 (PAI-1) is a single chain glycoprotein of 50 kDa. PAI-1 is secreted and is mainly produced by the endothelium, liver, and adipose tissue. It is also produced by certain tumours. PAI-1 activity is tightly regulated on the transcriptional level by transforming growth factor ß. PAI-1 is the principal inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA), which convert plasminogen to plasmin. Congenital PAI-1 deficiency can cause hemorrhagic diathesis. PAI-1 is present in larger amounts in various pathologies, such as in a number of cancers or obesity. In breast cancer, high levels of PAI-1 are associated with a high risk of recurrence.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|One Unit Contains||5000 assay points|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
|Resource Type||File Name||File Format|
|Data Sheet||Manual AlphaLISA Human PAI-1 AL286||PDF 237 KB|
|Poster||A Comparison of AlphaLISABead-Based Luminescence and Electrochemiluminescence Immunoassay Technologies for Detection of Human EPO, Amyloid Beta 42 and VEGF in Complex Sample Matrices||PDF 179 KB|
|Poster||AlphaLISA Assays are Homogeneous Sensitive Immunoassays for Detection of Analytesin a Variety of Biological Matrices||PDF 273 KB|